Thiazolidinediones as anti-inflammatory and anti-atherogenic agents.
about
The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolitesA randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosisEndothelial dysfunction as a target for prevention of cardiovascular disease.Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies.IL-17 regulates adipogenesis, glucose homeostasis, and obesity.The effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients: prospective randomized study with volumetric intravascular ultrasonography analysis.Retrospective review of superficial femoral artery stenting in diabetic patients: thiazolidinedione use may decrease reinterventions.Evidence from studies in rodents and in isolated adipocytes that agonists of the chemerin receptor CMKLR1 may be beneficial in the treatment of type 2 diabetes.Stimulatory interactions between human coronary smooth muscle cells and dendritic cells.Trials of antidiabetic drugs in amyotrophic lateral sclerosis: proceed with caution?Attenuation of Immune-Mediated Renal Injury by Telmisartan, an Angiotensin Receptor Blocker and a Selective PPAR-γ Activator.Synthesis of new pyrazolyl-2, 4-thiazolidinediones as antibacterial and antifungal agents.Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DMThiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanismInsulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instabilityHybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals.PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury.Endothelial dysfunction in metabolic and vascular disorders.Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia.Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-kappaB.Human interleukin-10 gene inhibits acute rejection by triggering apoptosis in allograft vascular transplantation.Rosiglitazone does not improve vascular function in subjects with chronic kidney disease.Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.Synthesis and in vitro antiproliferative and antibacterial activity of new thiazolidine-2,4-dione derivatives.Synthesis and Studies of Potential Antifungal and Antibacterial Agents New Aryl Thiazolyl Mercury (II) Derivatives Compounds
P2860
Q27664075-C0F29E72-8F7F-4822-A2EA-C393E934D13BQ28728672-7CE55884-BF86-48AD-8F51-7162DE0F61D3Q33610670-A235E6A2-A0F1-446C-8A4E-B27BA819AE0DQ34109242-B49F4363-ABC7-4B63-8B95-2B32200A3B1AQ34401701-927599AD-EA84-4FF2-B73F-96E2B4C73C3FQ34512533-40C8D5CE-0525-433F-B051-0F8D21931C9AQ34728813-0E73CCB2-57EE-466F-B569-A2C765F6044EQ35081441-F84013B9-871B-41CB-ADF2-1EC176F3ED37Q35188689-A22AE98F-9171-4E39-8112-EDAC75035F49Q35618724-5ECBAA0C-E747-409F-9198-21D721935AF7Q35791764-B57DBCF5-E75D-40EE-A4B7-A80CA5DB7A1FQ35872366-03089635-E98B-429A-84A6-4E5A9BFE5C82Q35932449-9FCAF0BC-E552-4384-B9D1-BF719647FB2DQ36555556-FC899695-D789-48E2-8874-1D5930CA9351Q36741853-1A23FC80-BA02-4D5F-AA64-5E399C0BCCA2Q36920492-C7179C36-6C60-4510-8A33-8BA47EF5CCA9Q37361545-1BEAA386-B6E0-445D-ADED-B2F860BFADCCQ38200828-80C1A18B-E005-4362-9357-EC1AD4E40BE1Q38823805-A4852FE2-EAEF-4C1B-A1C4-E08BABEB1164Q39769313-4D28EFAD-88E1-471E-86D4-96C2A0489CC3Q42183105-F4FE8C25-2340-44EE-AE89-2A2B6599568FQ44983950-8C4BE2D3-6AC8-4A81-B62D-71C7C10CDCE7Q51345495-54A3D662-2721-4F22-991A-93F379D69D99Q51768361-3FFC9F80-EC4E-4BCD-AF23-32EDF797707FQ59009055-F00B98A0-FAF7-4BDE-9B8F-EBA96C79A3A2
P2860
Thiazolidinediones as anti-inflammatory and anti-atherogenic agents.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Thiazolidinediones as anti-inflammatory and anti-atherogenic agents.
@en
type
label
Thiazolidinediones as anti-inflammatory and anti-atherogenic agents.
@en
prefLabel
Thiazolidinediones as anti-inflammatory and anti-atherogenic agents.
@en
P2860
P356
P1476
Thiazolidinediones as anti-inflammatory and anti-atherogenic agents.
@en
P2860
P356
10.1002/DMRR.790
P577
2008-01-01T00:00:00Z